# Junta clínica — PT-pseudo_8967e0df17fc (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_8967e0df17fc",
  "pid": "PT-pseudo_8967e0df17fc",
  "task": 1,
  "psa": 6.2,
  "age": 72,
  "months": 1,
  "pirads": "4",
  "psad": 0.269,
  "psav": 1.2,
  "psap": 5.2,
  "vol": 23.05,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8429154,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 6.2 ng/mL. PI-RADS 4. PSAD 0.27. Prostate volume 23 mL. csPCa 0.84.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "85 kg",
    "height": "182 cm",
    "bmi": "25.7",
    "bp": "128/88 mmHg",
    "hr": "63 bpm",
    "smoking": "Current smoker (31 pack-yr)",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "06 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment is requested in light of a prior biopsy bucket \"Positive\" and a steadily climbing PSA trajectory."
    },
    {
      "s": "History",
      "t": "A 72-year-old retired truck driver presents for ongoing assessment of his prostate cancer diagnosis alongside a recent PSA trajectory. He is married and shares a multi-generational household with his wife and adult child. While maintaining an active lifestyle that includes weekend hiking in the Veluwe, he experiences mild lower urinary tract symptoms, specifically occasional nocturia twice nightly, correlating with an IPSS score of 6/35. His alcohol intake averages 15 units weekly, and he is a Current smoker (31 pack-yr)."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal. Prostate symmetrically enlarged with smooth, firm consistency and absent nodules or asymmetry. General inspection reveals stable vital signs, adequate nutritional status, and no signs of acute distress. Respiratory and cardiac examinations are unremarkable, with no peripheral lymphadenopathy detected."
    }
  ],
  "occupation": "retired truck driver",
  "marital": "Married",
  "living": "Lives with adult child (multi-generational household)",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [],
  "alcohol": "15 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 6/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_8967e0df17fc
Task: 1

Encounter: Urology - outpatient on 06 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 6.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.269 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 5.2 ng/mL
  - Prostate volume: 23.05 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8429154 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.2 ng/mL. PI-RADS 4. PSAD 0.27. Prostate volume 23 mL. csPCa 0.84.

Vitals: weight 85 kg, height 182 cm, BMI 25.7, BP 128/88 mmHg, HR 63 bpm. Smoking: Current smoker (31 pack-yr).

Chief complaint: Clinical reassessment is requested in light of a prior biopsy bucket "Positive" and a steadily climbing PSA trajectory.

History: A 72-year-old retired truck driver presents for ongoing assessment of his prostate cancer diagnosis alongside a recent PSA trajectory. He is married and shares a multi-generational household with his wife and adult child. While maintaining an active lifestyle that includes weekend hiking in the Veluwe, he experiences mild lower urinary tract symptoms, specifically occasional nocturia twice nightly, correlating with an IPSS score of 6/35. His alcohol intake averages 15 units weekly, and he is a Current smoker (31 pack-yr).

Physical examination: DRE: Normal. Prostate symmetrically enlarged with smooth, firm consistency and absent nodules or asymmetry. General inspection reveals stable vital signs, adequate nutritional status, and no signs of acute distress. Respiratory and cardiac examinations are unremarkable, with no peripheral lymphadenopathy detected.

Patient info: retired truck driver; Married; Lives with adult child (multi-generational household).
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 15 units / week; exercise Hiking on weekends; IPSS score: 6/35 (mild LUTS).


Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.10 epistemic (95% band 0.46-0.85); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.64: PI-RADS 4, PSA 4.1, PSAD 0.181, age 72, DRE Normal -> BIOPSY (borderline). He wrote: "Borderline older patient, favorable intermediate risk disease with perineurial features. Low PSA (why was he biopsied in 2023 under non-elevated PSA?). While only one pr…"
  2. distance 0.92: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  3. distance 1.02: PI-RADS 4, PSA 7.8, PSAD 0.165, age 74, DRE Normal -> BIOPSY (clear). He wrote: "Active surveillance of unfavorable intermediate risk disease, no previous re-biopsy. Likely biopsied index lesion on MRI, but note small tumor extension on biopsy (4mm)…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. It also states that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk disease.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline makes the decision dependent on the MRI findings and PSA density, which are not explicitly resolved by the panel variables alone. The precedent cited by Expert 5 shows that the decision is highly dependent on the specific PI-RADS score and PSA level, which differs from this patient's profile.

WHAT WE STILL NEED
The panel already contains:
*   Prior biopsy status: Positive. This is important because the guideline suggests the histological grade of the prior biopsy is the strongest reason to trigger a change in management.
*   PI-RADS: 4. This is important as the guideline mentions that targeted and perilesional biopsies are taken for lesions of PI-RADS $\ge 3$.
*   PSA: 6.2 ng/mL. This is important as the guideline mentions that a PSA of 3-10 ng/mL in men without suspicious findings on palpation should prompt a second PSA test after four weeks.
*   PSA density: 0.269 ng/mL². This is important as the guideline mentions that a low PSA-D (< 0.15) may lead to omitting a repeat biopsy.
*   The grade of the prior biopsy: This is needed because the guideline states that histopathology criteria are the strongest reason to trigger a change in management.
*   The MRI prose: This is needed because the guideline states that a stable MRI (PRECISE 1-3) is a factor in deciding whether to omit a repeat biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the specific MRI prose to determine if the EAU criteria for repeat biopsy are met.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the MRI finding?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values beyond the headline value?
  previous_notes (get_previous_notes) -> What is the documented grade (Gleason/ISUP) of the prior biopsy, the number and dates of biopsy sessions, and surveillance status?
  laboratory_results (get_lab_results) -> What are the full laboratory results, including free-PSA fraction and renal function?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the Gleason or ISUP grade of the prior biopsy?
  Q2. What is the specific MRI prose regarding lesion size, zone, and extraprostatic extension?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Facility: Ziekenhuis Gelderse Vallei, Ede | Date: 02 Jan 2025
What is the lesion size and zone of the MRI finding? The T2-weighted sequences identify a 12 x 10 x 11 mm hypointense focus within the left mid-gland peripheral zone.

psa_trend
What is the trend of the serial PSA values beyond the headline value? The serial PSA values are: {"date": "Apr 2023", "val": 1.6}, {"date": "Sep 2023", "val": 2.2}, {"date": "Feb 2024", "val": 3.1}, {"date": "Aug 2024", "val": 4.4}, {"date": "Jan 2025", "val": 6.2}.

previous_notes
What is the documented grade (Gleason/ISUP) of the prior biopsy, the number and dates of biopsy sessions, and surveillance status? The documented grade (Gleason/ISUP) of the prior biopsy is not recorded. The number and dates of biopsy sessions are not recorded. Surveillance status is not recorded.

laboratory_results
What are the full laboratory results, including free-PSA fraction and renal function? PSA is "6.2 ng/mL" on "25 Nov 2024". Free PSA is "0.78 ng/mL" on "25 Nov 2024", and %Free PSA is "13%" on "25 Nov 2024". eGFR is ">60 mL/min/1.73m2" on "25 Nov 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already provided the relevant information regarding the prior biopsy status.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 4 lesion in the left mid-gland peripheral zone.
PSA trend shows a clear upward trajectory, culminating in a PSA of 6.2 ng/mL.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is not recorded.
The documented grade (Gleason/ISUP) of the prior biopsy is not recorded.

WHERE THIS LEANS
The findings point toward a need for further histological clarification due to the PI-RADS 4 finding and rising PSA, but the lack of prior biopsy grading leaves the definitive management path unclear.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 6.20 ng/mL over 5 points spanning 21 months; velocity +2.59 ng/mL per year; doubling time about 11 months.
PROJECTION at 6 months: 9.1 ng/mL, conformal 95% band 2.6-31.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.61
  uncertainty  +/- 0.10 epistemic (95% band 0.41-0.82), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.65  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.61  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.66 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed the moderator's questions to the extent that they provided data points, although the specific answers to Q1 and Q2 remain unstated in the retrieved text.

ALIGNMENT WITH THE PANEL
The retrieved evidence, particularly the PI-RADS 4 finding and the rising PSA trend, aligns with the panel's decision to recommend biopsy, as the panel relied on the weighted vote of experts when the crucial prior grade was missing.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the Gleason or ISUP grade of the prior biopsy? This question remains unanswered as the `previous_notes` report that the documented grade is not recorded.
Q2. What is the specific MRI prose regarding lesion size, zone, and extraprostatic extension? The `radiology_report` states a "12 x 10 x 11 mm hypointense focus within the left mid-gland peripheral zone," which addresses size and zone but not explicitly extraprostatic extension.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 4 finding and the rising PSA trend carry significant weight because they are explicitly noted as supporting factors for sampling, as highlighted by the trace model. The lack of the prior biopsy grade is the primary missing piece that prevents a definitive guideline-based decision.

MY SUGGESTION TO THE CHAIR
Given that the panel protocol defaulted to biopsy due to missing data, and the retrieved information supports further investigation (PI-RADS 4, rising PSA), the path forward should be to proceed with biopsy to obtain the necessary histological grade.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the PI-RADS 4 finding and the rising PSA trajectory, a biopsy is indicated to obtain the necessary histological grade for management planning. The decision was driven by the weighted vote of experts, as the crucial documented prior biopsy grade was missing from the retrieved notes. The evidence converged on the need for further histological clarification to guide the next step in this patient's care.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
